Lilly’s Diabetes Franchise Poised For A Shakeup As Conterno Steps Down
Executive Summary
Lilly’s newer diabetes drugs are selling well, although Trulicity numbers disappointed analysts, and are among the firm’s growth-drivers. Longtime diabetes head Enrique Conterno will be succeeded by insider Mike Mason.
You may also be interested in...
Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D
Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.
Did Lilly Overcome US Price Pressures In Last Quarter? Investors Await Answer
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.